
|Articles|December 6, 2021
Daily Medication Pearl: Lacosamide (Vimpat) Partial-Onset Seizures
Author(s)Saro Arakelians, PharmD
Advertisement
Medication Pearl of the Day: Lacosamide (Vimpat)
Lacosamide is indicated for the treatment of partial-onset seizures in patients 1 month of age and older, as well as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
Insight:
- Dosing: Initial dosage for monotherapy for the treatment of partial-onset seizures is 100 mg twice daily. Initial dosage for adjunctive therapy for the treatment of partial-onset seizures or primary generalized tonic-clonic seizures is 50 mg twice daily.
- Dosage forms: 50 mg, 100 mg, 150 mg, 200 mg tablets; 200 mg/20 mL single-dose vial for intravenous use; 10 mg/mL oral solution.
- Adverse events (AEs): Most common AEs in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence.
- Mechanism of action: Inhibition of neuronal firing.
- Manufacturer: ucbCARES
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
3
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
4
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
5

















































































































































































































